Hibah Awwad, Ph.D.
Traumatic brain injury (TBI) is a leading cause of death and disability in young adults. To date, there are no FDA-approved drugs for TBI. The main focus of our research is to study the mechanisms of neurotoxic factors released after a brain injury, in order to identify potential targets for novel neuroprotective therapies. Scientific methods include neuropharmacology via molecular, biochemical, behavioral and imaging techniques.
Publications & Presentations
- Baier M, Lerner M R, Awwad H O. Temporal changes in mast cell release following a mild traumatic brain injury in rats. Society for Neuroscience Annual Meeting Proceedings. 2017
- Oleru A V, Edwards A C, Awwad H O. Mild traumatic brain injury increases histamine-3-receptor expression. Journal of Neurotrauma. 2017; 34 : A-103
- Edwards A C, Johnston M P, Lerner M R, Abdelkader S H, Chen S, Awwad H O. Earlier recovery from vestibulomotor deficits compared to neurological deficits and increased pain sensitivity in rats with a mild traumatic brain injury. Society for Neuroscience Annual Meeting Proceedings. 2016
- Awwad H O, Durand C D, Gonzalez L P, Tompkins P, Zhang Y, Lerner M R, Brackett D J, Sherry D M, Awasthi V, Standifer K. Post-blast treatment with Nociceptin/Orphanin FQ peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions. Behavioural brain research. 2016
- Maltos K K, Stratton N C, Zhang Y, Awwad H O, Standifer K, M S D. Sources and suppression of autofluorescence in multi-channel immunofluorescent microscopy of formalin-fixed paraffin-embedded sections of brain and spinal cord tissue. J Histochem Cytochem. In Press